Assuming the worst, AbbVie took an impairment charge a few weeks later of $4 billion as doubts also spread about the other drugs that came in with Rova-T that also used the same cytotoxic agent.

I'll start by comparing the revenue growth rates of AbbVie and Sanofi, then move on to discuss how often these two leaders in the autoimmune disease treatment market beat Wall Street analysts ...

AbbVie recently showcased significant advances in oncology, particularly with the introduction of new pipeline products like ABBV-969 and ABBV-514 at the AACR Annual Meeting 2025, reflecting a ...